ER
EGRX

Enlightenment Research’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Enlightenment Research’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-300
Closed -$12K – 711
2018
Q4 		$12K Buy
+300
New +$15.5K 0.01% 553

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Enlightenment Research's EGRX Position: Q1 2019 in Review

Enlightenment Research sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2019, closing a stake of 300 shares — an estimated $12K sold.

Enlightenment Research first reported a position in EGRX in Q4 2018 and held it in 1 quarter. The position peaked at $12K in Q4 2018. 182 funds tracked by Wall St. Rank hold EGRX as of Q1 2019.

  • Enlightenment Research reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Enlightenment Research sold 300 Eagle Pharmaceuticals, Inc. shares in Q1 2019, an estimated $12K.
  • Enlightenment Research first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2018 and held it in 1 quarter.
  • Enlightenment Research's Eagle Pharmaceuticals, Inc. position peaked at $12K in Q4 2018.
  • 182 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2019.

Based on Enlightenment Research's 13F filing for Q1 2019, filed 3 May 2019.